Firebrick Pharma Limited (AU:FRE) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Firebrick Pharma Limited has announced plans to globally expand its product, Nasodine, now being marketed as a nasal antiseptic, addressing various unmet medical needs. The company has shared its commercialisation strategy and will host a webinar to discuss these developments, inviting shareholders and interested investors. This step follows the successful launch of Nasodine in the United States and Singapore, backed by multiple clinical trials confirming its safety and antimicrobial efficacy.
For further insights into AU:FRE stock, check out TipRanks’ Stock Analysis page.